key: cord-0699734-c4zwiuxa
authors: Yang, S.; Li, Y.; Dai, L.; Wang, J.; He, P.; Li, C.; Fang, X.; Wang, C.; Zhao, X.; Huang, E.; Wu, C.; Zhong, Z.; Wang, F.; Duan, X.; Tian, S.; Wu, L.; Liu, Y.; Luo, Y.; Chen, Z.; Li, F.; Li, J.; Yu, X.; Ren, H.; Liu, L.; Meng, S.; Yan, J.; Hu, Z.; Gao, L.; Gao, G. F.
title: Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
date: 2020-12-22
journal: nan
DOI: 10.1101/2020.12.20.20248602
sha: 337ee8ec9e159a8e0c7b36937067e3cb7b23433d
doc_id: 699734
cord_uid: c4zwiuxa

Background A safe and effective coronavirus disease 2019 (COVID-19) vaccine is urgently needed to control the ongoing pandemic. Although progress has been made recently with several candidates reporting positive efficacy results, COVID-19 vaccines developed so far cannot meet the global vaccine demand. We developed a protein subunit vaccine against COVID-19, using dimeric form of receptor-binding domain (RBD) as the antigen. We aimed to assess the safety and immunogenicity of this vaccine in humans and determine the appropriate dose and schedule for an efficacy study. Methods We did two randomized, double-blind, placebo-controlled, phase 1 and 2 trials for an RBD-based protein subunit vaccine, ZF2001. In phase 1 study, 50 healthy adults aged 18-59 years were enrolled and randomly allocated to three groups to receive three doses of vaccine (25 g or 50 g RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, 30 days apart. In phase 2 study, 900 healthy adults aged 18-59 years were enrolled and randomly allocated to six groups to receive vaccine (25 g or 50 g RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, with the former 3 groups given two doses and the latter 3 groups given three doses, 30 days apart. For phase 1 trial, the primary outcome was safety, as measured by the occurrence of adverse events and serious adverse events. The secondary outcome was immunogenicity as measured by the seroconversion rate and magnitude of antigen-binding antibodies, neutralizing antibodies and T-cell cytokine production. For phase 2 trial, the primary outcome included both safety and immunogenicity. These trials are registered with ClinicaTrials.gov, NCT04445194 and NCT04466085. Findings Between June 22 and September 15, 2020, 50 participants were enrolled to the phase 1 study (mean age 32.6 years) and 900 participants were enrolled to phase 2 study (mean age 43.5 years), to receive vaccine or placebo with a two-dose or three-dose schedule. For both trials, local and systemic adverse reactions were absent or mild in most participants. There were no serious adverse events related to vaccine in either trial. After three doses, neutralizing antibodies were detected in all participants receiving either 25 g or 50 g dose of vaccine in phase 1 study, and in 97% (the 25 g group) and 93% (the 50 g group) of participants, respectively, in phase 2 study. The SARS-CoV-2-neutralizing geometric mean titres (GMTs) were 94.5 for the 25 g group and 117.8 for the 50 g group in phase 1, and 102.5 for the 25 g group and 69.1 for the 50 g group in phase 2, exceeding the level of a panel of COVID-19 convalescent samples (GMT, 51). Vaccine induced balanced TH1 and TH2 responses. The 50 g group did not show enhanced immunogenicity compared with the 25 g group. Interpretation The protein subunit vaccine ZF2001 is well-tolerated and immunogenic. The safety and immunogenicity data from phase 1 and 2 trials for ZF2001 support the use of 25 g vaccine dose with three-dose schedule to an ongoing phase 3 large-scale evaluation for safety and efficacy. Funding National Program on Key Research Project of China, National Science and Technology Major Projects of Drug Discovery, Strategic Priority Research Program of the Chinese Academy of Sciences, and Anhui Zhifei Longcom Biopharmaceutical.

(RBD) as the antigen. We aimed to assess the safety and immunogenicity of this 87 vaccine in humans and determine the appropriate dose and schedule for an efficacy 88 study. 89 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in We did two randomized, double-blind, placebo-controlled, phase 1 and 2 trials for 92 an RBD-based protein subunit vaccine, ZF2001. In phase 1 study, 50 healthy adults 93 aged 18-59 years were enrolled and randomly allocated to three groups to receive 94 three doses of vaccine (25 μg or 50 μg RBD-dimer, with adjuvant) or placebo (adjuvant-95 only) intramuscularly, 30 days apart. In phase 2 study, 900 healthy adults aged 18-59 96 years were enrolled and randomly allocated to six groups to receive vaccine (25 μg or 97 50 μg RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, with the 98 former 3 groups given two doses and the latter 3 groups given three doses, 30 days 99 apart. For phase 1 trial, the primary outcome was safety, as measured by the 100 occurrence of adverse events and serious adverse events. The secondary outcome 101 was immunogenicity as measured by the seroconversion rate and magnitude of 102 antigen-binding antibodies, neutralizing antibodies and T-cell cytokine production. For 103 phase 2 trial, the primary outcome included both safety and immunogenicity. These 104 trials are registered with ClinicaTrials.gov, NCT04445194 and NCT04466085. Between June 22 and September 15, 2020, 50 participants were enrolled to the 108 phase 1 study (mean age 32.6 years) and 900 participants were enrolled to phase 2 109 study (mean age 43.5 years), to receive vaccine or placebo with a two-dose or three-110 dose schedule. For both trials, local and systemic adverse reactions were absent or 111 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in To response the pandemic, we launched a vaccine development program against 155 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The phase 1 trial was conducted at two hospitals in China: The Second Affiliated 176

Hospital of Chongqing Medical University (Chongqing) and Beijing Chao-Yang 177 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The trial was designed with double-blind, randomized and placebo-parallel-193 controlled. Participants in phase 1 were divided into 3 groups at a ratio of 2:2:1 and 194 allocated to receive three doses of vaccine (25 μg or 50 μg antigen dose) or placebo 195 on day 0, 30 and 60. Participants in phase 2 were divided into six groups at a 196 1:1:1:1:1:1 ratio, with the former three groups receiving two doses of vaccine (25 μg or 197 50 μg antigen dose) or placebo, 30 days apart, while the latter three groups receiving 198 three doses of vaccine (25 μg or 50 μg antigen dose) or placebo, 30 days apart. 199 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in and not allowed to disclose the blind code to any personnel participating in this clinical 214 trial. The participants were randomly assigned to the experimental vaccine group or 215 the placebo group according to the block randomisation method, with the block and 216 block size of 5 and 5, respectively, in phase 1 trial, and of 75 and 12, respectively, in 217 phase 2 trial. Investigators at trial site assign study numbers strictly according to the 218 order of screening sequence of eligible subjects, and experimental vaccines were 219 obtained and administered according to the numbers. The participants, field 220 investigators and laboratory team were always blinded to group allocation during the 221 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Laboratory safety tests including routine blood, and serum chemistry and routine urine 244 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The funders of the study had no role in data collection, data analysis, data 303 interpretation, or writing of the Article. All authors had full access to all the data in the 304 study and had final responsibility for the decision to submit for publication. In phase 1, a total of 107 volunteers were recruited and screened for eligibility 309 between June 22 and July 3, 2020 in Chongqing and Beijing, China (figure 1). 57 310 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in participants was 32.6 years (SD 9.41; range 20.9-57.9), with balanced age and sex 314 distribution among vaccination groups (table 1) In phase 2, a total of 1085 volunteers were recruited and screened for eligibility 319 between July 12 and July 17, 2020, in Xiangtan, China (figure 1). 185 volunteers were 320 excluded, and 900 volunteers were enrolled to participant the trial. They were randomly 321 assigned to 6 groups (n=150) to receive vaccine (25 μg or 50 μg RBD-dimer, with 322 adjuvant) or placebo (adjuvant-only) with either a two-dose or a three-dose schedule, 323 30 days apart. The mean age of the participants was 43.5 years (SD 9.17; range 18.8-324 59.7) with balanced age and sex distribution among vaccination groups (table 1) reported by 0%, 5% and 15%; fever, reported by 0%, 10% and 0%; and headache, 341 reported by 0%, 5%, 5% (figure 2, appendix 2). Two grade 3 (or above) adverse events 342 (10%) were reported in the 50 μg group. One was vaccine-related (swelling and 343 redness) and the other one was serious adverse event (rhabdomyolysis), but was 344 vaccine-unrelated as assessed by the investigators (appendix 9). No vaccine-related 345 serious adverse events or adverse events of special interest were reported. 346

In phase 2 trial, the overall adverse events were low within 30 days after vaccination. The most common solicited local adverse reactions in placebo, the 25 μg and 50 μg 354 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint groups were injection-site pain, reported by 4%, 3% and 5% in two-dose participants, 355 3%, 12% and 12% in three-dose participants; swelling, reported by 1%, 4% and 6% in 356 two-dose participants, 1%, 14% and 13% in three-dose participants; induration, 357 reported by 1%, 3% and 5% in two-dose participants, 0%, 9% and 7% in three-dose 358 participants; redness, reported by 1%, 8% and 8% in two-dose participants, 1%, 16% 359 and 14% in three-dose participants; and itch, reported by 0%, 6% and 9% in two-dose 360 participants, 0%, 19% and 17% in three-dose participants. The most common solicited 361 systemic adverse reactions in the placebo, the 25 μg and 50 μg groups were fever, 362 reported by 4%, 5% and 7% in two-dose participants, 8%, 8% and 7% in three-dose 363 participants; cough, reported by 1%, 2% and 2% in two-dose participants, 1%, 1% and 364 0% in three-dose participants; and headache, reported by reported by 1%, 2% and 1% 365 in two-dose participants, 0%, 2% and 0% in three-dose participants; and fatigue, 366 reported by 0%, 3% and 2% in two-dose participants, 3%, 0% and 0% in three-dose 367 participants ( figure 2, appendix 3) . 18 participants were reported grade 3 (or above) 368 adverse events, with 12 of them (1.3%) were vaccine-related, including redness (5 369 cases), swelling (3 cases), injection-site pain (1 cases), induration (1 case), headache 370

(1 case) and cough (1 case). Seven participants were reported serious adverse events, 371 but none of them were considered to related to the study vaccine as assessed by the 372 investigators (appendix 9). Besides, no adverse events of special interest were 373

Regarding to the immunogenicity, in phase 1 trial we detected the serologic RBD-375 binding IgG titers by ELISA assay to assess the antibody responses. The baseline 376 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint antibody titres of the participants are shown in the appendix 4. At day 30 after the first 377 immunization, the seroconversion rates were 61% for the 25 μg group and 79% for the 378 50 μg group; and were increased to 100% for both groups at day 30 after the second perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint

The GMT of neutralizing antibodies for the COVID-19 convalescent serum panel was 399 51 (95% CI, 38.3-70.5). Encouragingly, the neutralizing GMTs for both the 25 μg and 400 50 μg groups were approximately two times of the magnitude than human 401 convalescent samples ( figure 3D) . 402

In phase 2 trial, the baseline antibody titres of the participants are shown in the 403 appendix 4. At day 30 after the first immunization, the seroconversion rates were 59% 404 and 65% for the 25 μg and 50 μg group, respectively, in two-dose participants; 63% 405 and 62% for the 25 μg and 50 μg group, respectively, in three-dose participants. At day 406 30 after the second immunization, the seroconversion rates were increased to 95% 407 and 97% for the 25 μg and 50 μg group, respectively, in two-dose participants; 96% 408 and 94% for the 25 μg and 50 μg, respectively, in three-dose participants. At day 14 409 after the third immunization, the seroconversion rates were further increased to 99% perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in figure 3F; appendix 7) . Regarding to the neutralizing antibody titres against live SARS-424

CoV-2, seroconversion rates and GMTs were analyzed. For the participants with two-425 dose schedule, 76% and 72% were seroconverted in the 25 μg and 50 μg group, 426 respectively, at 14 days after the 2 nd immunization (appendix 8). For the participants 427 with three-dose schedule, 83% and 73% were seroconverted at 14 days after the 2 nd 428 immunization in the 25 μg and 50 μg group, respectively; and further increased to 97% 429 and 93%, respectively, at 14 days after the 3 rd immunization ( figure 3G, appendix 8) . Seroconversion rates (A and E) and geometric mean titres (GMTs) (B and F) of RBD-574 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint 667 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint

Description of the First Strain of 2019-nCoV, C-Tan-nCoV Wuhan Strain 584 -National Pathogen Resource Center

Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to 587 start next week

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine 589 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised 590 controlled trial

Safety and immunogenicity of an rAd26 and rAd5 vector-based 592 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-593 randomised phase 1/2 studies from Russia

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 595 administered in a prime-boost regimen in young and old adults (COV002): a single-596 blind, randomised, controlled, phase 2/3 trial

Immunogenicity and safety of a recombinant adenovirus type-5-598 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, 599 double-blind, placebo-controlled, phase 2 trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus 601 type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, 602 first-in-human trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, 604 BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 607 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-608 controlled, phase 1/2 clinical trial

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine 611 in Older Adults

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein 615

Nanoparticle Vaccine

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine 617 Candidates

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. 619

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell 621 responses

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and 623 All rights reserved. No reuse allowed without permission

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

Viral targets for vaccines against COVID-19

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) 630 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

Covid-19: Moderna applies for US and EU approval as vaccine trial reports 634 94.1% efficacy

Warp Speed" Needs Mind Melds, Not 636 Warped Minds

The receptor binding domain of the viral spike protein is an 638 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Subunit Vaccines Against Emerging Pathogenic 641

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human 643 ACE2

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, 645 and SARS

Bat-to-human: spike features determining 'host jump' of 647 coronaviruses SARS-CoV, MERS-CoV, and beyond

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2

Humans during a Fishery Vessel Outbreak with a High Attack Rate

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus 655 macaques

Development of an inactivated vaccine candidate for SARS-CoV-2. 657

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with 659 Potent Protection against SARS-CoV-2

Generation of a Broadly Useful Model for COVID-19 Pathogenesis

T-cell immunity of SARS-CoV: Implications for vaccine development 663 against MERS-CoV

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic 665 or Mild COVID-19

Learning from the past: development of safe and effective COVID-19 vaccines

All rights reserved. No reuse allowed without permission. perpetuity

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint 21 cytokines IFN-γ, IL-2 and the TH2 cytokines IL-4, IL-5. As expected, placebo group did 443 not show obvious increase for all tested T-cell cytokines. By contrast, either the 25 μg 444 or 50 μg group elicited moderate levels of both TH1 (IFN-γ and IL-2) and TH2 (IL-4 and 445 IL-5) cytokine production post vaccinations ( figure 4) We found vaccination with different doses (25 or 50 μg) and schedules (two-or three-460 doses) were well-tolerated. The incidents of adverse reactions between vaccine 461 groups and placebo groups were similar in both phase 1 and 2 trials, without statistical 462 significance. Most of the adverse reactions were mild, with the most common 463 symptoms being injection-pain, redness and swelling. These adverse reactions were 464 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in of the convalescent selected for comparison, our study indicated encouragingly that 484 ZF2001 has the potential to elicit protective humoral responses against Three-dose vaccination was found dramatically enhanced the antibody responses 486 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in This trial report has several limitations. First, the participants in both trials were 499 young adults aged from 18-59, not including juvenile and elderly persons, whereas, 500 the elderly is more vulnerable to SARS-CoV-2. Moreover, the participants had limited 501 ethnic diversity, mainly the ethnic Han. These limitations will be addressed by our 502 outreach study for cohort covering broader age range and ethnic backgrounds. Second, 503 the immunogenicity was tested at day 30 post full vaccination in phase 1 and day 14 504 post full vaccination in phase 2, which cannot be assessed for the duration of the 505 immune response. Immune responses at later timepoints including those at least 6 506 months post vaccination will be obtained in the follow-up visits and investigation. Third, 507 there was still no benchmark to evaluate protective immune responses against COVID-508 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint 24 19. Therefore, although ZF2001 induced neutralizing GMTs higher than the 509 convalescent samples, it is yet hard to predict its protective efficacy. Since no 510 participant had SARS-CoV-2 exposure, we were unable to assess the protective 511 efficacy and vaccine-associated enhanced diseases at this moment. This limitation will 512 be addressed in the ongoing international multi-center phase 3 trials. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Individual participant data will be made available on request, directed to the 539 corresponding author (GFG). After approval of a proposal, data can be shared through 540 a secure online platform. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.20.20248602 doi: medRxiv preprint